Pregnancy and pandemics: Interaction of viral surface proteins and placenta cells

2021 ◽  
pp. 166218
Author(s):  
Paulina Fuentes-Zacarías ◽  
Jose M. Murrieta-Coxca ◽  
Ruby N. Gutierrez-Samudio ◽  
Astrid Schmidt ◽  
Andre Schmidt ◽  
...  
Keyword(s):  
Surface Proteins ◽  
Viral Surface

scholarly journals Targeting Viral Surface Proteins through Structure-Based Design

Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1320
Author(s):  
Yogesh B Narkhede ◽  
Karen J Gonzalez ◽  
Eva-Maria Strauch
Keyword(s):  
Public Health ◽  
Viral Infections ◽  
Respiratory Viruses ◽  
Surface Proteins ◽  
Host Cells ◽  
Viral Fusion ◽  
Health It ◽  
Viral Particles ◽  
Pathogenic Viruses ◽  
Viral Surface

The emergence of novel viral infections of zoonotic origin and mutations of existing human pathogenic viruses represent a serious concern for public health. It warrants the establishment of better interventions and protective therapies to combat the virus and prevent its spread. Surface glycoproteins catalyzing the fusion of viral particles and host cells have proven to be an excellent target for antivirals as well as vaccines. This review focuses on recent advances for computational structure-based design of antivirals and vaccines targeting viral fusion machinery to control seasonal and emerging respiratory viruses.

Melittin-loaded immunoliposomes against viral surface proteins, a new approach to antiviral therapy

2013 ◽  
Vol 97 (2) ◽  
pp. 218-221 ◽  
Author(s):  
Alberto Falco ◽  
Enrique Barrajón-Catalán ◽  
María P. Menéndez-Gutiérrez ◽  
Julio Coll ◽  
Vicente Micol ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Surface Proteins ◽  
New Approach ◽  
Viral Surface

scholarly journals Human cytomegalovirus-infected cells release extracellular vesicles that carry viral surface proteins

Virology ◽  
2018 ◽  
Vol 524 ◽  
pp. 97-105 ◽  
Author(s):  
Sonia Zicari ◽  
Anush Arakelyan ◽  
Rogers Alberto Ñahui Palomino ◽  
Wendy Fitzgerald ◽  
Christophe Vanpouille ◽  
...  
Keyword(s):  
Extracellular Vesicles ◽  
Human Cytomegalovirus ◽  
Surface Proteins ◽  
Infected Cells ◽  
Viral Surface

scholarly journals Isolation and Partial Characterization of an Antiviral Proteolytic Fraction from the Venom of Echis Carinatus Sochureki

2008 ◽  
Vol 1 (1) ◽  
pp. 21-26 ◽  
Author(s):  
G. Borkow ◽  
D. Marco ◽  
M. Ovadia
Keyword(s):  
Molecular Weight ◽  
Hemolytic Activity ◽  
Sendai Virus ◽  
Surface Proteins ◽  
Gelatinase Activity ◽  
Sds Page ◽  
Virion Envelope ◽  
Echis Carinatus ◽  
Viral Surface

The venom of the viper Echis carinatus sochureki suppresses the hemolytic activity of Sendai virus on human erythrocytes, when pre-incubated with the virions prior to their binding to cells. A fraction (C1), with an IC50 of 1.25 􀀁g/ml, was isolated from the venom. Fraction C1 possesses strong azocollase, azocaseinase and gelatinase activity. The proteolytic and anti-hemolytic potency of C1 depends on the period and temperature of incubation. Its antiviral activity is inhibited by Sodium-EDTA but not by PMSF. SDS PAGE of Sendai virus incubated with fraction C1 shows disappearance of several of the virion high molecular weight bands. We suggest that inhibition of the hemolytic activity of the virions is probably a result of the cleavage of viral surface proteins, such as the hemagglutinin-neuraminidase glycoprotein found on the virion envelope that mediates the absorption of the virus to cells.

scholarly journals Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19

Viruses ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 1324
Author(s):  
Kenneth Lundstrom
Keyword(s):  
Neutralizing Antibodies ◽  
Viral Vectors ◽  
Vaccine Development ◽  
Viral Vector ◽  
Recombinant Protein Expression ◽  
Surface Proteins ◽  
Viral Particles ◽  
Preclinical Animal Models ◽  
Viral Surface ◽  
Lethal Doses

Viral vectors can generate high levels of recombinant protein expression providing the basis for modern vaccine development. A large number of different viral vector expression systems have been utilized for targeting viral surface proteins and tumor-associated antigens. Immunization studies in preclinical animal models have evaluated the elicited humoral and cellular responses and the possible protection against challenges with lethal doses of infectious pathogens or tumor cells. Several vaccine candidates for both infectious diseases and various cancers have been subjected to a number of clinical trials. Human immunization trials have confirmed safe application of viral vectors, generation of neutralizing antibodies and protection against challenges with lethal doses. A special emphasis is placed on COVID-19 vaccines based on viral vectors. Likewise, the flexibility and advantages of applying viral particles, RNA replicons and DNA replicon vectors of self-replicating RNA viruses for vaccine development are presented.

A proof of concept for structure-based vaccine design targeting RSV in humans

Science ◽  
2019 ◽  
Vol 365 (6452) ◽  
pp. 505-509 ◽  
Author(s):  
Michelle C. Crank ◽  
Tracy J. Ruckwardt ◽  
Man Chen ◽  
Kaitlyn M. Morabito ◽  
Emily Phung ◽  
...  
Keyword(s):  
Subunit Vaccine ◽  
Vaccine Development ◽  
Vaccine Candidate ◽  
Level Structure ◽  
Vaccine Design ◽  
Atomic Level ◽  
Surface Proteins ◽  
Proof Of Concept ◽  
Syncytial Virus ◽  
Viral Surface

Technologies that define the atomic-level structure of neutralization-sensitive epitopes on viral surface proteins are transforming vaccinology and guiding new vaccine development approaches. Previously, iterative rounds of protein engineering were performed to preserve the prefusion conformation of the respiratory syncytial virus (RSV) fusion (F) glycoprotein, resulting in a stabilized subunit vaccine candidate (DS-Cav1), which showed promising results in mice and macaques. Here, phase I human immunogenicity data reveal a more than 10-fold boost in neutralizing activity in serum from antibodies targeting prefusion-specific surfaces of RSV F. These findings represent a clinical proof of concept for structure-based vaccine design, suggest that development of a successful RSV vaccine will be feasible, and portend an era of precision vaccinology.

Stimulierung der Immunreaktivität gegen endogene Retroviren und Schutz gegen Leukämie bei älteren AKR-Mäusen nach Impfung mit Antikörpern gegen Virusoberflächen-Komponenten. Rolle des Antikörpers gegen p15(E) / Stimulation of Immunoreactivity against Endogenous Retroviruses and Protection against Leukem ia of Older AKR Mice by Treatment with Antibodies against Retroviral Surface Components. Role of p15 (E) Antibody

1984 ◽  
Vol 39 (11-12) ◽  
pp. 1199-1202 ◽  
Author(s):  
Heinz Schwarz ◽  
H.-J. Thiel ◽  
Kent J. Weinhold ◽  
Dani P. Bolognesi ◽  
Werner Schäfer
Keyword(s):  
Endogenous Retroviruses ◽  
Surface Proteins ◽  
Endogenous Virus ◽  
Antibody Treatment ◽  
Immunodeficiency Syndrome ◽  
Akr Mice ◽  
Viral Surface ◽  
Stimulation Of

Abstract Antibody against viral gp71 is effective therapeutically for high leukemic AKR mice if injected immediately after birth [1], No corresponding effect could be observed after inoculation later in life when the endogenous virus burden is already high. However, if antibody treatment was supplemented by the injection of pi5(E) antibody, a thera­peutic effect was observed even in older mice first treated at an age of 21/2 months. Those mice produced antibodies against viral surface proteins and appeared to be able to survive longer than control mice. Thus pi5(E) antibody might be able to overcome retroviral associated immuno­deficiency. This therapy may have implications for the treatment of the apparently retroviral induced aquired immunodeficiency syndrome (AIDS) of man.

Immune blot analysis of viral surface proteins in serum and liver of patients with chronic hepatitis B virus infection

1989 ◽  
Vol 29 (4) ◽  
pp. 261-265 ◽  
Author(s):  
Guido Gerken ◽  
Michael Manns ◽  
Wolfram H. Gerlich ◽  
Georg Hess ◽  
Karl-Hermann Meyer Zum Büschenfelde
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Blot Analysis ◽  
Surface Proteins ◽  
Hepatitis B Virus Infection ◽  
Chronic Hepatitis B Virus ◽  
B Virus ◽  
Viral Surface

scholarly journals The potential for antibody-dependent enhancement of SARS-CoV-2 infection: Translational implications for vaccine development

2020 ◽  
pp. 1-4 ◽  
Author(s):  
Jiong Wang ◽  
Martin S. Zand
Keyword(s):  
Monoclonal Antibody ◽  
Virus Infection ◽  
Dengue Virus ◽  
Vaccine Development ◽  
Surface Proteins ◽  
Dengue Virus Infection ◽  
Antibody Dependent Enhancement ◽  
High Affinity ◽  
Viral Surface

Abstract There is an urgent need for vaccines to the 2019 coronavirus (COVID19; SARS-CoV-2). Vaccine development may not be straightforward, due to antibody-dependent enhancement (ADE). Antibodies against viral surface proteins can, in some cases, increase infection severity by ADE. This phenomenon occurs in SARS-CoV-1, MERS, HIV, Zika, and dengue virus infection and vaccination. Lack of high-affinity anti-SARS-CoV-2 IgG in children may explain the decreased severity of infection in these groups. Here, we discuss the evidence for ADE in the context of SARS-CoV-2 infection and how to address this potential translational barrier to vaccine development, convalescent plasma, and targeted monoclonal antibody therapies.

Sign in / Sign up

Export Citation Format

Share Document